Breast cancer
Results
Phase 3
This trial looked at pembrolizumab for early stage breast cancer that doesn’t have receptors for progesterone, oestrogen or HER2. This is called triple negative breast cancer.
The trial was open for people to join from 2017 to 2018. The research team presented the first results at a conference in 2019.
Recruitment start: 7 March 2017
Recruitment end: 30 September 2018
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Peter Schmid
Merck Sharp & Dohme Ltd
Last reviewed: 14 Oct 2020
CRUK internal database number: 14852
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
